This blog post was authored by Emily Henkle, PhD, MPH, and reviewed by the Bronchiectasis and NTM Content Review and Evaluation Committee.

Hello BronchandNTM360social community!

We are sharing exciting news -- the MAC2v3 clinical trial led by Dr. Kevin Winthrop and team at Oregon Health & Science University completed enrollment in October 2024. This study is important to the NTM lung disease community as it is designed to test whether two drugs (azithromycin and ethambutol) are as helpful in treating MAC (a common type of NTM) as the “big three” (azithromycin, ethambutol, and rifampin) in producing a negative sputum culture. The researchers are also studying whether two drugs are easier to tolerate than three.

We surpassed our target enrollment of 466 participants with 474 entered into the study. We will be presenting preliminary data at the American Thoracic Society conference in May. However, the MAC2v3 study cannot report results until all the data is in. The study data collection will be complete in October 2025, and we plan to review the results by the end of the year.

We continue to meet with our study advisory committee and patient advisory panel to review data.

We are grateful to the patients, families, and our amazing network of 30+ physicians at 22 sites in North America, from Hawaii to New York to Texas to Toronto, Canada, that contributed to this study.

For more information: visit www.MAC2v3study.org or clinicaltrials.gov [#NCT03672630]

Thanks for reading! Emily Henkle, PhD, MPH
MAC2v3 Co-investigator
OHSU-PSU School of Public Health Portland, OR